{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:35:20Z","timestamp":1773837320830,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"CANTAM"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ijid.2019.02.025","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T12:13:16Z","timestamp":1551096796000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection"],"prefix":"10.1016","volume":"82","author":[{"given":"Simon Marie","family":"Peko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerly Shir\u00e8re Gampio","family":"Gueye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christevy","family":"Vouvoungui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Koukouikila-Koussounda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Charles","family":"Kobawila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nderu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thirumalaisamy P.","family":"Velavan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4748-050X","authenticated-orcid":false,"given":"Francine","family":"Ntoumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0005","first-page":"13","article-title":"Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the Mozambican population","volume":"20","author":"Arnaldo","year":"2013","journal-title":"Malays J Med Sci"},{"issue":"8","key":"10.1016\/j.ijid.2019.02.025_bib0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/157016212803901338","article-title":"Correlation of CYP2B6-516G>T polymorphism with plasma efavirenz concentration and depression in HIV-infected adults in Northern Thailand","volume":"10","author":"Aurpibul","year":"2012","journal-title":"Curr HIV Res"},{"issue":"3","key":"10.1016\/j.ijid.2019.02.025_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090350","article-title":"Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)","volume":"9","author":"Borand","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ijid.2019.02.025_bib0020","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2165\/00003495-200666180-00003","article-title":"Tuberculosis and HIV co-infection: a practical therapeutic approach","volume":"66","author":"Breen","year":"2006","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2125.2012.04163.x","article-title":"Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices","volume":"74","author":"Calcagno","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/FTD.0b013e318274197e","article-title":"Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor","volume":"35","author":"Cortes","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijid.2019.02.025_bib0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40360-015-0004-2","article-title":"CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV\/AIDS and TB cohort in Zimbabwe","volume":"16","author":"Dhoro","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ijid.2019.02.025_bib0040","first-page":"213","article-title":"Global tuberculosis incidence and mortality during 1990\u20132000","volume":"72","author":"Dolin","year":"1994","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ijid.2019.02.025_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2014.04.011","article-title":"Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population","volume":"33","author":"Fernandes","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2019.02.025_bib0050","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","article-title":"Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence","volume":"38","author":"Fumaz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.ijid.2019.02.025_bib0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","article-title":"The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis","volume":"68","author":"Gengiah","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2019.02.025_bib0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-6405-7-32","article-title":"Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients","volume":"7","author":"Gounden","year":"2010","journal-title":"AIDS Res Ther"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":"Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.ijid.2019.02.025_bib0070","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(09)70320-2","article-title":"Pharmacogenetics of antimalarial drugs: effect on metabolism and transport","volume":"9","author":"Kerb","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"10.1016\/j.ijid.2019.02.025_bib0075","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1097\/QAD.0b013e32830163ad","article-title":"Clinical impact of patient population differences and genomic variation in efavirenz therapy","volume":"22","author":"King","year":"2008","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.ijid.2019.02.025_bib0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/01213011-200512000-00004","article-title":"Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz","volume":"15","author":"Klein","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03368.x","article-title":"CYP2B6 (c. 516G>T) and CYP2A6 (*9B and\/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients","volume":"67","author":"Kwara","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ijid.2019.02.025_bib0090","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/AAC.00980-10","article-title":"Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers","volume":"55","author":"Kwara","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2019.02.025_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0100","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"Luetkemeyer","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2019.02.025_bib0105","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.02023-12","article-title":"Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug\u2013drug interaction on efavirenz concentrations in HIV\/tuberculosis-coinfected patients","volume":"57","author":"Manosuthi","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijid.2019.02.025_bib0110","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2217\/pgs.14.48","article-title":"Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics","volume":"15","author":"Martin","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijid.2019.02.025_bib0115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/1475-2875-13-420","article-title":"Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations","volume":"13","author":"Marwa","year":"2014","journal-title":"Malar J"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1155\/2012\/453479","article-title":"Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients","volume":"32","author":"Masebe","year":"2012","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-005-0092-9","article-title":"Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea","volume":"62","author":"Mehlotra","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ijid.2019.02.025_bib0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/pr.111.005553","article-title":"The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition","volume":"64","author":"Michaud","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ijid.2019.02.025_bib0140","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Population. Minist\u00e8re de la Sant\u00e9 et de la Population: Politique nationale de lutte contre le paludisme; 2006. Retrieved from Brazzaville, Republic of Congo."},{"key":"10.1016\/j.ijid.2019.02.025_bib0145","unstructured":"MOH. Le Fonds mondial Rapport 2017 sur les r\u00e9sultats; 2017. Retrieved from https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/corporate_2017resultsreport_report_fr.pdf."},{"issue":"5","key":"10.1016\/j.ijid.2019.02.025_bib0150","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans","volume":"68","author":"Mukonzo","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ijid.2019.02.025_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067946","article-title":"Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations","volume":"8","author":"Ngaimisi","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","article-title":"High prevalence of the CYP2B6 516G>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe","volume":"64","author":"Nyakutira","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2019.02.025_bib0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.meegid.2015.08.003","article-title":"CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon","volume":"35","author":"Paganotti","year":"2015","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.ijid.2019.02.025_bib0170","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Population. Programme de Lutte contre la Tuberculose au Congo: Rapport final 2014."},{"issue":"7","key":"10.1016\/j.ijid.2019.02.025_bib0175","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00297-17","article-title":"Pharmacokinetics of efavirenz at a high dose of 25 milligrams per kilogram per day in Children 2 to 3 years old","volume":"61","author":"Pressiat","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.02.025_bib0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman","year":"2017","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.ijid.2019.02.025_bib0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.00899-08","article-title":"CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India","volume":"53","author":"Ramachandran","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"10.1016\/j.ijid.2019.02.025_bib0195","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1097\/QAD.0b013e32832e95f8","article-title":"Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial","volume":"23","author":"Read","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2019.02.025_bib0200","unstructured":"Sant\u00e9, M.d.l. Rapport nationalsur la reponse au vih\/sida; 2013. Retrieved from http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/GAB_narrative_report_2014.pdf."},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0205","doi-asserted-by":"crossref","first-page":"16594","DOI":"10.4238\/2015.December.11.6","article-title":"Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing","volume":"14","author":"Scibona","year":"2015","journal-title":"Genet Mol Res"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0009-9236(03)00092-4","article-title":"Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9","volume":"74","author":"Simonsson","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0215","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bcp.12590","article-title":"Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa","volume":"80","author":"Sinxadi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ijid.2019.02.025_bib0220","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","article-title":"Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania","volume":"57","author":"Staehli Hodel","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2019.02.025_bib0225","first-page":"356","article-title":"An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3\u2032-UTR single nucleotide polymorphisms among Black South African HIV\/AIDS patients","volume":"6","author":"Swart","year":"2015","journal-title":"Front Genet"},{"issue":"8","key":"10.1016\/j.ijid.2019.02.025_bib0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","article-title":"High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients","volume":"23","author":"Swart","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.ijid.2019.02.025_bib0235","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/aid.2006.0193","article-title":"No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART","volume":"23","author":"Takahashi","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijid.2019.02.025_bib0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.pharmtox.48.113006.094753","article-title":"Pharmacogenetics of anti-HIV drugs","volume":"48","author":"Telenti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0245","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.antiviral.2009.09.001","article-title":"Pharmacogenetics of antiretrovirals","volume":"85","author":"Tozzi","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijid.2019.02.025_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"10.1016\/j.ijid.2019.02.025_bib0255","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/phar.1852","article-title":"Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection","volume":"36","author":"Vo","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0260","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085905","article-title":"The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1","volume":"9","author":"Xiang","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ijid.2019.02.025_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001809","article-title":"Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients","volume":"3","author":"Yimer","year":"2008","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ijid.2019.02.025_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ijid.2019.02.025_bib0280","first-page":"685","article-title":"Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: implications for malaria and HIV\/AIDS treatment","volume":"17","author":"Zakeri","year":"2014","journal-title":"Arch Iran Med"},{"issue":"1","key":"10.1016\/j.ijid.2019.02.025_bib0285","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ijid.2019.02.025_bib0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"4","key":"10.1016\/j.ijid.2019.02.025_bib0295","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121930089X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197121930089X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T10:24:15Z","timestamp":1562581455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197121930089X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":59,"alternative-id":["S120197121930089X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.02.025","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome P450 CYP2B6*6 distribution among Congolese individuals with HIV, Tuberculosis and Malaria infection","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}